-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
India Imposes 162.5% Duty on Bulk Scotch Imports Amid UK Trade Pact Dispute
-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
Inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® follows the Company's August 2026 initial public offering and takes effect with FTSE Russell's December 2026 reconstitution
RALEIGH, NC / ACCESS Newswire / November 19, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it is set to join the broad-market Russell 2000®, Russell 3000® Index, and Russell Microcap® Index as part of FTSE Russell's December 2026 semi-annual reconstitution of the Russell US Indexes. Membership will take effect after the U.S. equity markets close on Friday, December 11, 2026, according to the preliminary list of additions FTSE Russell published on November 13, 2026.
Russell index membership is determined by objective, rules-based criteria, chiefly total market capitalization as of the rank day. The December 2026 reconstitution is the first December reconstitution of the Russell US Indexes in more than three decades, following FTSE Russell's move to a semi-annual (June and December) schedule this year.
"Joining the Russell indexes just four months after our IPO is an important milestone for Vogenx," said James Green, Chief Executive Officer of Vogenx. "Index inclusion broadens our visibility with institutional and index-based investors at a time when we are advancing mizagliflozin in our Phase 2b EMERGE study for post-bariatric hypoglycemia, a serious condition with no FDA-approved treatment. We look forward to engaging with a wider investor base as we work toward key clinical milestones."
About the Russell US Indexes
The Russell US Indexes, maintained by FTSE Russell, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. The Russell 3000® Index measures the performance of the broad U.S. equity market, and the Russell 2000® Index, a subset of the Russell 3000, is a leading benchmark for U.S. small-capitalization companies. Beginning in 2026, the Russell US Indexes are reconstituted twice a year, in June and December.
About Mizagliflozin
Mizagliflozin is an investigational, first-in-class, orally administered, minimally absorbed small-molecule inhibitor of the sodium-dependent glucose transporter 1 (SGLT1). Designed to act locally in the small intestine, mizagliflozin reduces and delays intestinal glucose absorption, lowering postprandial glucose absorption. It has been studied in more than 500 subjects across 10 clinical studies. Vogenx holds an exclusive license to mizagliflozin from Kissei Pharmaceutical Co., Ltd. covering all territories outside Japan, Korea and Taiwan.
About Vogenx, Inc.
Vogenx, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism where there is significant unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected inclusion in the Russell 3000®, Russell 2000® and Russell Microcap® Indexes, the timing thereof, the anticipated benefits of index inclusion, and the Company's clinical development plans and milestones. Index membership remains subject to FTSE Russell's final determination. Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "will" and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this release, and Vogenx specifically disclaims any obligation to update them, except as required by law.
Contacts
Harrison Seidner, PhD and Nilesh Talele, PhD
WaterSeid Partners, Inc.
[email protected]
SOURCE: Vogenx, Inc.
View the original press release on ACCESS Newswire
A.Moore--AT